Skip to main content

Expression of topoisomerase II and Ki-67 in cervical carcinoma – clinicopathological study using immunohistochemistry

Buy Article:

$43.00 plus tax (Refund Policy)


To study the correlation between the expression of topoisomerase II and Ki-67 antigen and disease outcome in cervical squamous cell carcinomas. Experimental design.

Forty-nine cervical carcinomas, 10 cases of high-grade cervical intraepithelial neoplasia (CIN II-III) and 5 control cervices were stained by monoclonal antibodies for topoisomerase II and Ki-67 (MIB-1 clone). Nuclear counts were correlated with patient age, tumor stage, histological grade and survival. Results.

Thirteen patients died of disease, 35 remained free of disease, and one patient was lost to follow up. Ki-67 counts were higher in CIN lesions, when compared to both invasive carcinomas and control cervices. Topoisomerase II counts were comparable for CIN and invasive tumors. No immunoreactivity for topoisomerase was detected in control cases. Neither stage nor grade was associated with nuclear counts using either marker. In multivariate survival analysis, stage (p=0.001), grade (p=0.03) and older patient age (p=0.02) predicted poor survival. Ki-67 counts predicted survival with borderline significance (p=0.07), while topoisomerase II counts were not related to survival. Conclusion.

Ki-67 and topoisomerase II counts do not appear to have a significant role in the prediction of survival in cervical squamous cell carcinoma.
No References
No Citations
No Supplementary Data
No Data/Media
No Metrics

Keywords: Ki-67; cervical intraepithelial neoplasia; patient survival; squamous cell carcinoma; topoisomerase II; uterine cervix

Document Type: Original Article

Affiliations: 1: and Clinical Epidemiology 2: and Division of Gynecologic Oncology 3: , Sheba Medical Center, Tel Hashomer, Affiliated with Sackler School of Medicine, Tel-Aviv University, Israel

Publication date: 2000-03-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more